Navigation Links
Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
Date:3/27/2009

e, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2008; and other risks detailed from time-to-time in our public filings, financial statements and other in
'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
2. Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results
3. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
4. Warner Chilcott Reports the Death of Its Director James Andress
5. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
6. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
7. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
8. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
9. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
10. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
11. Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... 29, 2014 Three Lawrence Livermore ... Hydrogen Production R&D Award for their ... water using sunlight. , Shared with collaborators from ... University of Nevada, Las Vegas (UNLV), the award ... of photoelectrochemical solar-hydrogen production and corrosion processes. , ...
(Date:8/29/2014)... MA (PRWEB) August 29, 2014 A ... in the biotech start-up dense realm of Boston-Cambridge, is ... and able investors. James Sherley, the Director of Boston’s ... increasing the local and national visibility of his company ... September 2013. , In addition to a social media ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... Exagen Diagnostics, Inc. , a specialty focused ... tests for rheumatologists and gastroenterologists, announced today the appointment ... Tornoe has more than 20 years of ... making him a key hire as Exagen broadens its ...
... LOS ANGELES, Aug. 10, 2011 Genesis Biopharma, ... cancer immunotherapies, today announced it has signed a ... National Cancer Institute (NCI).  Under the terms of ... Biopharma will work with Steven A. Rosenberg, M.D., ...
... DIEGO, Aug. 9, 2011 Verenium Corporation (Nasdaq: ... development and commercialization of high-performance enzymes, today reported a summary ... quarter and six months ended June 30, 2011. ... terms of product revenues and partnership negotiations in the first ...
Cached Biology Technology:Eric Tornoe Joins Exagen Diagnostics as President and COO 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9
(Date:8/28/2014)... Yale University researchers have identified a handful of bacterial ... as Crohn,s disease and ulcerative colitis, using patients, own ... are published Aug. 28 in the journal Cell ... intestinal microbiota, which plays a critical role in the ... only a small number of bacterial species affect a ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program has ... of Human Genetics from October 18 22, 2014 ... to promote the entry of students, post doctorates and ... basic science community and to encourage the participation of ... This year MARC conferred 16 awards totaling $29,600., ...
(Date:8/28/2014)... The support of peer groups and clinicians ... programs, according to recent University of Georgia research. ... the Athens-Clarke County area determined that role models ... of mothers of infants. , "Mothers who received ... at breastfeeding," said study co-author Alex Anderson, an ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2Breastfeeding study shows need for effective peer counseling programs 2
... is available in German . , ... species of the Galapagos archipelago, treks slowly and untiringly ... Institute for Ornithology in Radolfzell, together with the Charles ... acceleration measurements to find out that especially the dominant ...
... A study published in the current issue ... available on-line at http://www.ingentaconnect.com/content/cog/ct/ , has found ... (SM-MSCs) or adipose tissue (ADSCs) were injected into ... laboratory rats that had suffered a myocardial infarction, ...
... more than 200 million people every year mainly in ... the Plasmodium parasite, which is spread by infected ... but more than half a million people nevertheless die every ... during the past decade have reduced the distribution of the ...
Cached Biology News:Galapagos tortoises are a migrating species 2Galapagos tortoises are a migrating species 3Study suggests different organ-derived stem cell injections improve heart function 2New method for diagnosing malaria 2
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
... Life Science FLA-8000 Fluorescent Image Analyzer features ... single laser imaging system. This powerful new ... with fluorescent dyes or radioisotopes at resolutions ... laboratories. Speed, image quality and flexibility make ...
...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Biology Products: